| answer text |
<p>The National Institute for Health and Care Excellence COVID-19 rapid guideline
on severe asthma provides guidance on starting or continuing on biological treatments,
for people with severe asthma during the COVID-19 outbreak. The recommendations were
written in collaboration with the NHS England Severe Asthma Collaborative. In writing
the guidance, particular attention was paid to streamlining the process of moving
patients onto biologic therapies to compensate for any possible barriers that may
have occurred as a result of changes to the National Health Service, which were made
as part of the necessary response to COVID-19.</p><p>Further work is being undertaken
by the collaborative to share best practice on providing care to people with severe
asthma to ensure on-going provision of high-quality care and to accelerate the initiation
of biologics where required.</p>
|
 |
